Cme (CME) EBITDA (2009 - 2026)

Cme (CME) has reported EBITDA for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 1.84% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $4.5 billion, a 4.65% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 7.58% from the prior year.
• EBITDA was $1.1 billion for Q2 2026 at Cme, down from $1.3 billion in the prior quarter.
• Over five years, EBITDA peaked at $1.3 billion in Q1 2026 and troughed at $668.3 million in Q4 2022.
• A 5-year average of $969.4 million and a median of $968.4 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA grew 29.16% in 2023 and declined 5.07% in 2025, its largest moves.
• Over 5 years, EBITDA stood at $668.3 million in 2022, then rose by 29.16% to $863.2 million in 2023, then advanced by 9.72% to $947.1 million in 2024, then climbed by 7.65% to $1.0 billion in 2025, then gained by 11.35% to $1.1 billion in 2026.
• The last three EBITDA figures came in at $1.1 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.